NEW YORK (GenomeWeb News) – Australian molecular diagnostics developer Genera Biosystems said today that its upcoming initial public offering has closed oversubscribed, with demand for shares outweighing the number of shares offered.
The company expects its stock will begin trading on the Australian Stock Exchange under the ticker symbol GBI during the first week of June. Genera said it expects its market capitalization to be around AU $25 million ($24.1 million) when it begins trading.
Genera’s first product is the PapType, a test for human papillomavirus, and it also has another test for other sexually transmitted diseases in advanced pre-clinical development.